摘要
随着钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)在临床上的广泛应用,越来越多的研究结论指出其不仅在糖尿病患者中具有良好血糖控制效果,并且对非糖尿病,尤其是存在心力衰竭的患者,具有优异的心血管保护作用,可通过多重机制来显著减少心律失常的发生。目前上市的SGLT2i药物包括达格列净、恩格列净、卡格列净等,均有应用于心律失常患者中的相关报道,其作用机制涉及影响离子通道、提高心脏对能量利用效率、减少脂肪酸积累等多个方面。该综述旨在通过回顾近些年的相关文献,重点分析SGLT2i在防治心律失常中的作用及潜在机制,并以期为未来进一步阐明SGLT2i在不同心律失常类型中的应用潜力提供参考。
With the widespread clinical application of sodium-glucose cotransporter 2 inhibitors(SGLT2i),an increasing number of studies have highlighted their beneficial effects not only in blood glucose control in diabetic patients but also in providing significant cardiovascular protection in non-diabetic individuals,particularly those with heart failure.These drugs can significantly reduce the occurrence of arrhythmias through multiple mechanisms.Currently marketed SGLT2i drugs,including Dapagliflozin,Empagliflozin,and Canagliflozin,have been reported to be beneficial in arrhythmic patients.Their mechanisms of action involve modulation of ion channels,enhancement of cardiac energy utilization efficiency,and reduction of fatty acid accumulation,among others.This review aims to analyze the role of SGLT2i in the prevention and treatment of arrhythmias and their underlying mechanisms by reviewing the relevant literature in recent years,and to provide a reference for future studies to clarify the potential applications of SGLT2i in various arrhythmia types.
作者
于蕾
刘赢
YU Lei;LIU Ying(Department of Cardiology,Jinan Third People's Hospital,Jinan 250100,China;不详)
出处
《中国医学创新》
2025年第21期180-184,共5页
Medical Innovation of China
